TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
+47.15%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$876M
AUM Growth
+$876M
(+19%)
Cap. Flow
-$231M
Cap. Flow
% of AUM
-26.38%
Top 10 Holdings %
Top 10 Hldgs %
56.33%
Holding
40
New
2
Increased
1
Reduced
6
Closed
2
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$23.2M |
| 2 |
Dyne Therapeutics
DYN
|
$10.6M |
| 3 |
Enliven Therapeutics
ELVN
|
$9.99M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$96.5M |
| 2 |
RAPT Therapeutics
RAPT
|
$91.6M |
| 3 |
Mineralys Therapeutics
MLYS
|
$39.2M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$21.7M |
| 5 |
CMPS
Compass Pathways
CMPS
|
$11M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $95.4M | 10.9% | 3,670,206 | – | – |
|
2
Tango Therapeutics
TNGX
$747M
| $55M | 6.28% | 10,736,000 | – | – |
|
3
Cogent Biosciences
COGT
$1.69B
| $50M | 5.71% | 6,964,375 | – | – |
|
4
Ocular Therapeutix
OCUL
$2.12B
| $49.4M | 5.64% | 5,319,148 | – | – |
|
5
Cidara Therapeutics
CDTX
$1.66B
| $49M | 5.6% | 1,005,901 | – | – |
|
|
ABVX
6
Abivax
ABVX
$6.12B
| $46.3M | 5.29% | 6,056,596 | – | – |
|
7
Amylyx Pharmaceuticals
AMLX
$836M
| $38.1M | 4.35% | 5,943,812 | – | – |
|
|
CNTA
8
Centessa Pharmaceuticals
CNTA
$2.25B
| $38M | 4.34% | 2,890,816 | – | – |
|
9
Fulcrum Therapeutics
FULC
$351M
| $36.1M | 4.13% | 5,250,000 | – | – |
|
|
10
Dyne Therapeutics
DYN
$1.92B
| $35.9M | 4.1% | 3,766,660 +1,116,510 | +42% | +$10.6M |
|
11
EyePoint Pharmaceuticals
EYPT
$797M
| $33.6M | 3.84% | 3,572,335 | – | – |
|
|
UPB
12
Upstream Bio, Inc. Common Stock
UPB
$923M
| $30.8M | 3.51% | 2,801,763 | – | – |
|
13
Savara
SVRA
$567M
| $28.2M | 3.22% | 12,362,205 | – | – |
|
14
Dianthus Therapeutics
DNTH
$759M
| $28M | 3.2% | 1,501,624 | – | – |
|
15
Tyra Biosciences
TYRA
$675M
| $27.7M | 3.17% | 2,898,103 | – | – |
|
16
Disc Medicine
IRON
$2.07B
| $24.6M | 2.81% | 465,257 | – | – |
|
17
Tourmaline Bio
TRML
$601M
| $23.6M | 2.7% | 1,477,593 | – | – |
|
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $23.2M | 2.65% | +697,003 | New | +$23.2M |
|
19
Structure Therapeutics
GPCR
$1.11B
| $22M | 2.52% | 1,063,000 | – | – |
|
20
Xencor
XNCR
$580M
| $19.3M | 2.2% | 2,452,138 | – | – |
|
|
SLN
21
Silence Therapeutics
SLN
$227M
| $17.6M | 2.01% | 3,033,560 | – | – |
|
22
Soleno Therapeutics
SLNO
$3.6B
| $15.6M | 1.78% | 186,250 -88,750 | -32% | -$7.44M |
|
23
Astria Therapeutics
ATXS
$349M
| $14.8M | 1.69% | 2,761,861 | – | – |
|
|
24
RAPT Therapeutics
RAPT
$188M
| $13.1M | 1.5% | 1,636,275 -11,453,925 | -88% | -$91.6M |
|
|
THRD
25
DELISTED
Third Harmonic Bio
THRD
| $10.4M | 1.19% | 1,915,424 -590,000 | -24% | -$3.2M |
|